Existing psychotropic nomenclature (e.g., “atypical antipsychotics”) falls quite short of being accurate or useful. Here, Dr. Joseph Goldberg will take a deep dive into the issues with current nomenclature -including the impact on clinician behavior, patient outcomes, and stigma. The evolving proposals for revising psychotropic nomenclature to reflect pharmacology and mechanism will be investigated. Specifically, issues arising from the use of outdated “atypical antipsychotic” and “antidepressant” terminology will be explored as well as the evidence base, approvals, and indications of various psychotropic medication classes in the treatment of mood disorders. After taking part in this educational activity, it is hoped that attendees will become a part of the nomenclature solution by ceasing use of antiquated terms and adopting updated, neuroscience-centered psychotropic nomenclature.
Claim Credits
The program evaluation and CME certificate will be available on April 28, 2025.
- Create a new account at nei.global/createaccount or use your existing nei.global account
- Complete your evaluation at https://nei.global/aapp2025-mood-eval
- Download or print your certificate
Questions? Email CustomerService@neiglobal.com or phone 888-535-5600 (Mon-Fri: 9am-5pm Pacific)
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Joseph F. Goldberg, MD
Clinical Professor, Department of Psychiatry
Icahn School of Medicine at Mount Sinai
Learning Objectives
- Appreciate the consequences of our current psychotropic nomenclature to optimal management and outcomes of mood disorders
- Evaluate the many approvals and evidence-based uses of serotonin dopamine antagonists/partial agonists (SDA-PAs) in the treatment of mood disorders
- Collaborate with patients and members of the care team to integrate SDA-PAs into the treatment of mood disorders in a way that optimizes acceptance, adherence, and outcomes
- Advocate for the widespread adoption of more appropriate and useful psychotropic nomenclature
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.